Skip to main content
. 2023 Apr 11;14:1146468. doi: 10.3389/fphar.2023.1146468

FIGURE 8.

FIGURE 8

Chemotherapeutic responses in high- and low-CuRGscore patients with LUAD. (A) Common drug sensitivity and resistance for high- and low-risk patients with LUAD using pRRophetic analysis in the training and external validation cohorts. (B, C) Drug resistance for receptor tyrosine kinases inhibitor, MP470 (B), and ALK5 inhibitor, SB52334 (C) in high-risk patients with LUAD. (D, E) Drug sensitivity for ALK F1174L and ALK R1275Q inhibitor, CH5424802 (D), and CDK1 inhibitor, RO-3306 (E), in high-risk patients with LUAD. (F–H) Chemotherapeutic sensitivity for mitosis inhibitors, such as vinblastine (F), paclitaxel (G) and docetaxel (H) in high-risk patients with LUAD. (I) Chemotherapeutic sensitivity for protein stability and degradation (lenalidomide) in high-risk patients with LUAD. (J–L) Chemotherapeutic sensitivity for DNA replication, including vinblastine (J), paclitaxel (K), and Cisplatin (L) in high-risk patients with LUAD. (M) Drug sensitivity for metabolism regulator, AICAR, in high-risk patients with LUAD.